proposal describes specialized center research scor ischemic heart disease tests hypothesis genetics expression function cardiovascular estrogen receptors er estrogenregulated target genes mediate protection ischemic diseases sequelae including vascular dysfunction post myocardial infarction remodeling arrhythmias program based widely noted gender differences ischemic disease beneficial effects estrogen cardiovascular diseases women recent data demonstrating 1 presence functional er cardiovascular diseases women men 2 important er target genes cardiovascular tissues 3 important role er genes regulate vascular myocardial physiology hypothesis investigated genetic molecular cellular animal human five highly integrated cooperative expand existing strengths new england medical center tufts university well mit boston university framingham heart five proposed include 1 genetics estrogen cardiovascular responses genetic analysis cardiovascular phenotypes ererrelated genes subjects framingham offspring 2 selective er modulation effects post menopausal women following myocardial infarction secondary prevention trial new england medical center selective er modulator raloxifene 3 cardiac er mi mouse models ventricular remodeling arrhythmogenic changes myocardial gene expression wildtype eralphako erbetako ventricular remodeling arrhythmogenic changes myocardial gene expression wildtype eralphako erbetako mice following mi 4 er regulation synthases rapid activation endothelial enos eralpha longerterm induction vascular smooth muscle inos gene expression erbeta 5 er smooth muscle bkca channels er regulation ion channel function ins ingle vascular smooth muscle cells served three cores administrative mouse transgenic physiology cell culture histology components statistical build existing cores molecular cardiology research institute tuftsnemc together five define broadbased program explore new mechanisms coronary myocardial regulation er direct consequences diagnosis management ischemic cardiovascular diseases potential evolve new class therapies disorders